Draft Guidance on Halobetasol Propionate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Halobetasol Propionate

Dosage Form; Route: Lotion; topical

Recommended Studies: Two studies

1. Type of study: Pilot Vasoconstrictor Study

   Design: Pilot dose duration-response study using the reference product under un-occluded conditions
   Strength: 0.05%
   Subjects: Healthy males and non-pregnant, non-lactating females, general population
   Additional comments: Refer to the guidance “Topical Dermatological Corticosteroids: In Vivo Bioequivalence”.

2. Type of study: Pivotal Vasoconstrictor Study

   Design: Pivotal in vivo bioequivalence study under un-occluded conditions
   Strength: 0.05%
   Subjects: Healthy males and non-pregnant, non-lactating females, general population
   Additional comments: See comments above.

Analytes to measure (in appropriate biological fluid): Not Applicable

Bioequivalence based on (90% CI): Pivotal Vasoconstrictor Study

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times: Not Applicable